JP2022516660A5 - - Google Patents
Info
- Publication number
- JP2022516660A5 JP2022516660A5 JP2021539621A JP2021539621A JP2022516660A5 JP 2022516660 A5 JP2022516660 A5 JP 2022516660A5 JP 2021539621 A JP2021539621 A JP 2021539621A JP 2021539621 A JP2021539621 A JP 2021539621A JP 2022516660 A5 JP2022516660 A5 JP 2022516660A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- fusion antibody
- seq
- glb1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789953P | 2019-01-08 | 2019-01-08 | |
| US62/789,953 | 2019-01-08 | ||
| PCT/US2020/012549 WO2020146359A1 (en) | 2019-01-08 | 2020-01-07 | Methods and compositions for increasing galactosidase beta-1 activity in the cns |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022516660A JP2022516660A (ja) | 2022-03-01 |
| JP2022516660A5 true JP2022516660A5 (cg-RX-API-DMAC10.html) | 2023-01-06 |
Family
ID=71521947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539621A Pending JP2022516660A (ja) | 2019-01-08 | 2020-01-07 | ＣＮＳにおけるガラクトシダーゼβ－１活性を増加させるための方法および組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20210403584A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3908611A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2022516660A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020146359A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013507131A (ja) | 2009-10-09 | 2013-03-04 | アーメイゲン・テクノロジーズ・インコーポレイテッド | Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物 |
| EP4526351A2 (en) * | 2022-05-16 | 2025-03-26 | City of Hope | Anti-cd84 antibodies and uses thereof |
| JP2025533863A (ja) * | 2022-10-12 | 2025-10-09 | ノベルファーマ株式会社 | Ｇｍ１ガングリオシド症又はモルキオ症候群ｂ型の治療、予防又は改善用薬学的組成物及びその投与方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020082224A1 (en) * | 1997-01-14 | 2002-06-27 | Douglas J. Jolly | Non-immunogenic prodrugs and selectable markers for use in gene therapy |
| US20050142141A1 (en) * | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
| US7932032B2 (en) * | 2005-05-02 | 2011-04-26 | Toray Industries, Inc. | Method for diagnosing esophageal cancer |
| CA2641070C (en) * | 2006-02-06 | 2017-01-03 | Ramot At Tel-Aviv University Ltd. | Enzyme replacement therapy for treating lysosomal storage diseases |
| WO2008051854A2 (en) * | 2006-10-20 | 2008-05-02 | Trustees Of Boston University | A tunable genetic switch for regulating gene expression |
| WO2010108048A2 (en) * | 2009-03-18 | 2010-09-23 | Armagen Technologies, Inc. | Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins |
| AU2012272815B2 (en) * | 2011-06-22 | 2017-09-07 | The General Hospital Corporation | Treatment of proteinopathies |
| EP2764119A2 (en) * | 2011-10-05 | 2014-08-13 | Genelux Corporation | Method for detecting replication or colonization of a biological therapeutic |
| US10538589B2 (en) * | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| CA2990785C (en) * | 2015-06-24 | 2024-11-12 | Jcr Pharmaceuticals Co., Ltd. | ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER |
-
2020
- 2020-01-07 WO PCT/US2020/012549 patent/WO2020146359A1/en not_active Ceased
- 2020-01-07 EP EP20738170.8A patent/EP3908611A4/en not_active Withdrawn
- 2020-01-07 US US17/295,390 patent/US20210403584A1/en not_active Abandoned
- 2020-01-07 JP JP2021539621A patent/JP2022516660A/ja active Pending
-
2025
- 2025-01-28 US US19/039,422 patent/US20250179201A1/en active Pending